scispace - formally typeset
Open AccessJournal ArticleDOI

Enhancement of photodynamic therapy in gastric cancer cells by removal of iron

W.C. Tan, +3 more
- 01 Jul 1997 - 
- Vol. 41, Iss: 1, pp 14-18
Reads0
Chats0
TLDR
Accumulation of PPLX and ultimately the efficacy of PDT could be improved by modulating both ends of the haem biosynthetic pathway by removal of available iron with desferrioxamine.
Abstract
BACKGROUND: Aminolaevulinic acid (ALA) is an endogenous substrate in the haem biosynthetic pathway. Protoporphyrin IX (PPIX), the immediate haem precursor in the pathway, has photoexcitable properties. Exogenous ALA has been used previously as a precursor agent in photodynamic therapy (PDT). Its main advantage is a short half-life and hence reduced incidence of skin photosensitivity. ALA can be toxic, however, causing, for example, transient increases in liver enzyme concentrations when given systemically and this may be dose related. AIM: To assess whether accumulation of PPLX and ultimately the efficacy of PDT could be improved by modulating both ends of the haem biosynthetic pathway. METHODS: Gastric cancer cells (MKN 28) were incubated with ALA (0-1000 mumolar) and desferrioxamine (0-800 mumolar) for 24 hours before exposure to argon-pumped dye laser (630 nm) at different energy levels (0-40 J/cm2). Cell viability was assessed by use of the methyl-tetrazolium (MTT) assay four hours after exposure to light. RESULTS: Total PPIX accumulation increased linearly with increasing extracellular concentrations of ALA up to 1 mmolar (r = 0.973, p

read more

Citations
More filters
Journal ArticleDOI

Aminolevulinic Acid (ALA) as a Prodrug in Photodynamic Therapy of Cancer

TL;DR: Since PpIX is a potent photosensitizer this metabolic pathway can be exploited in photodynamic therapy (PDT), this is an already approved therapeutic strategy making ALA one of the most successful prodrugs used in cancer treatment.
Journal ArticleDOI

Targeted Photodynamic Therapy

TL;DR: Photodynamic therapy (PDT) is an emerging modality for the treatment of various neoplastic and non‐neoplastic pathologies.
Journal ArticleDOI

The effect of an iron chelating agent on protoporphyrin IX levels and phototoxicity in topical 5‐aminolaevulinic acid photodynamic therapy

TL;DR: In 5‐aminolaevulinic acid (ALA)‐photodynamic therapy (PDT), the prodrug ALA is endogenously converted to the active sensitizer protoporphyrin IX (PpIX), while further conversion of PpIX to haem requires iron.
Journal ArticleDOI

Direct Comparison of δ-Aminolevulinic Acid and Methyl-Aminolevulinate-Derived Protoporphyrin IX Accumulations Potentiated by Desferrioxamine or the Novel Hydroxypyridinone Iron Chelator CP94 in Cultured Human Cells

TL;DR: The use of iron chelators in combination with ALA or MAL was shown to significantly increase the amount of PpIX accumulating in the fetal lung fibroblasts and epidermal carcinoma cells; while minimal enhancement was observed in the normal skin cells investigated.
Journal ArticleDOI

In Vivo and In Vitro Studies of Bacillus subtilis Ferrochelatase Mutants Suggest Substrate Channeling in the Heme Biosynthesis Pathway

TL;DR: The enzyme was studied in the bacterium Bacillus subtilis, for which the ferrochelatase three-dimensional structure is known, and the function of Q63 remains unclear, it is suggested that S54 is involved in substrate reception or delivery of the enzymatic product.
References
More filters
Journal Article

Protein Measurement with the Folin Phenol Reagent

TL;DR: Procedures are described for measuring protein in solution or after precipitation with acids or other agents, and for the determination of as little as 0.2 gamma of protein.
Journal Article

Identification of singlet oxygen as the cytotoxic agent in photoinactivation of a murine tumor

TL;DR: The protective effect against photodynamic inactivation of the TA-3 cells afforded by 1,3-diphenylisobenzofuran coupled with the nearly quantitative formation of the singlet oxygen-trapping product indicates that Singlet oxygen is the probable agent responsible for toxicity in this system.
Journal ArticleDOI

Photodynamic Therapy in Oncology: Mechanisms and Clinical Use

TL;DR: Clinically, this therapy has been chiefly used for palliation of endobronchial and esophageal obstruction, as well as for treatment of bladder carcinomas, skin malignancies, and brain tumors, and the future of PDT rests in defining its use either as an intraoperative adjuvant to marginal surgical procedures or as a primary treatment for superficial malignancy.
Journal ArticleDOI

Superficial photodynamic therapy with topical 5-aminolaevulinic acid for superficial primary and secondary skin cancer.

TL;DR: For large areas of Bowen's disease, particularly in anatomically difficult areas and in elderly patients, PDT using ALA may constitute a single simple alternative outpatient treatment to existing therapies.
Journal ArticleDOI

Photosensitisation and photodynamic therapy of oesophageal, duodenal, and colorectal tumours using 5 aminolaevulinic acid induced protoporphyrin IX--a pilot study

TL;DR: Photodynamic therapy with systemically administered ALA may be a promising technique for the treatment of small tumours and areas of dysplasia such as in Barrett's oesophagus.
Related Papers (5)